Skip to main content
News & Events

Genesis Research Group acquires Market Access Transformation, a leading provider of technology-enabled payer research platforms

By May 10, 2022November 11th, 2023No Comments

MAT RPR Rapid Payer Response logoGenesis Research Group, a leading provider of tech-enabled Real-World Evidence (RWE) and Health Economics and Outcomes Research (HEOR) services, has acquired Market Access Transformation (“MAT”), a leading provider of technology-enabled payer research platforms.

The highly complementary addition of MAT will further enhance Genesis Research Group’s offering by helping life sciences companies generate insights and evidence faster and more comprehensively than has ever been done before. The acquisition will increase Genesis Research Group’s headcount from 145 to 215 across four international locations.

MAT is an industry leader that specializes in developing agile technology platforms that enable life sciences companies to gather insights and assess the commercial viability of their products quickly and with rigor. Its two technology platforms have revolutionized the way companies conduct payer research and evaluate the market access viability of their products.

MAT’s Rapid Payer Response™ (RPR) platform enables manufacturers to capture more robust payer insights, in a third of the time and at half the cost compared to traditional-payer research approaches. RPR is powered by an expansive global payer network spanning over 50 countries and leveraging a unique payer selection and vetting process. MAT’s Envision™ is the only syndicated research platform that provides forward thinking evaluations of the market access viability for a product after it has received positive EMA or FDA guidance.

Genesis Research Group is a pioneering firm that has changed the way life sciences companies outsource RWE and HEOR with a science first, tech-enabled research offering. With an established footprint in the US and UK and a global service offering, Genesis Research Group optimizes drug development and evidences the clinical and commercial value of products via expert analysis, synthesis, communication and utilization of Real-World Data.

In 2021, Global Healthcare Opportunities, or GHO Capital Partners LLP (“GHO”), the European specialist investor in global healthcare, announced its investment in Genesis Research Group.

Frank A. Corvino, Chief Executive Officer of Genesis Research Group said: “The life sciences sector has repeatedly seen the challenges associated with demonstrating the value of new products. The combination of Genesis Research Group and MAT creates a novel and unparalleled approach to generating payer insights and evidence. This will enable life sciences companies to both identify and answer the right questions faster than ever before, without sacrificing scientific rigor or transparency.”

David Miller, PhD, Chairman of Genesis Research Group and Operating Partner at GHO said: “Genesis has established the market leading RWE and HEOR platform and this transaction strengthens this even further, enabling more opportunity for rapid international growth. Both companies share a common mission of optimizing patient access through accelerated excellence and I am excited to welcome our new colleagues to support us in achieving this.”

Baiju Aurora, Chief Executive Officer of Market Access Transformation, commented: “Less than two years after receiving our first institutional investment from Silversmith Capital Partners, we are excited to join Genesis Research Group, a rapidly growing company which shares our commitment to revolutionizing the way clients evaluate the commercial viability of their products. Together, we are building a market-leading organization capable of providing high-quality insights with faster timelines.”

Paul Howard, Co-Founder of Market Access Transformation added: “From the beginning MAT has developed agile technology platforms that enable life sciences companies to gather expert payer insights faster than ever before. We look forward to working with our new colleagues and continuing to provide the highest quality insights and evidence for our clients as part of Genesis Research Group.”

About Genesis Research Group
Genesis Research Group is an international Health Economics and Outcomes Research (HEOR) and Real-World Evidence (RWE) research organization that supports the life sciences industry. As a leader in evidence strategy, generation and communication, the company also supports pharmaceutical and biotech clients with tech-enabled, dedicated partnerships delivered via a unique engagement model that enables life sciences companies to quickly and comprehensively address complex needs with unmatched timeliness and quality. For more information, visit

About Market Access Transformation
Founded by industry veterans, MAT specializes in developing cutting edge technologies that enable the healthcare community to gather and exchange insights that assess the real-world potential of their products. MAT offers an online, information exchange platform, Rapid Payer Response™ (RPR), that allows healthcare stakeholders to secure immediate, expert feedback from the largest and most diverse online global payer network. For more information, visit

About Silversmith Capital Partners
Founded in 2015, Silversmith Capital Partners is a Boston-based growth equity firm with $2.0 billion of capital under management. Silversmith’s mission is to partner with and support the best entrepreneurs in growing, profitable technology and healthcare companies. Representative investments include ActiveCampaign, DistroKid,, Iodine Software, LifeStance Health, and Webflow. The partners have served on the boards of numerous successful growth companies including ABILITY Network,, Liberty Dialysis, Passport Health, SurveyMonkey, and Wrike. For more information about Silversmith, please visit or follow the firm on LinkedIn.

About GHO Capital
Global Healthcare Opportunities, or GHO Capital Partners LLP, is a leading specialist healthcare investment advisor based in London. We apply global capabilities and perspectives to unlock high growth healthcare opportunities, targeting Pan-European and transatlantic internationalisation to build market leading businesses of strategic global value. Our proven investment track record reflects the unrivalled depth of our industry expertise and network. We partner with strong management teams to generate long-term sustainable value, improving the efficiency of healthcare delivery to enable better, faster, more accessible healthcare. For further information, please visit


111 River Street, Suite 1120
Hoboken, New Jersey 07030, US